The data indicate CLYM116 showed a favourable safety profile, with no serious adverse events or dose-limiting toxicities.

Vera stock jumped Tuesday on positive test results for its kidney disease treatment, a rival to drugs from Otsuka and Vertex ...

TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints, including unprecedented placebo-adjusted estimated glomerular filtration rate (eGFR) and composite ...

Alebund Pharmaceuticals has received FDA IND clearance for AP308, a first-in-class engineered IgA protease designed to ...

ROCKVILLE, Md., July 20, 2026 (GLOBE NEWSWIRE)-- Today, the American Kidney Fund (AKF) and the IgA Nephrology Foundation announce the creation of a new resource for IgA nephropathy patients and their ...

On September 15, 2026, Vera Therapeutics, Inc. submitted a Form 8-K to the SEC revealing that TRUTAKNA (atacicept-vymj) ...

Limited ('Alebund' or the 'Company'; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that it has recently received clearance from the U.S. Food and Drug Administration (FDA) ...

Mississippi awarded more than $104 million in federal rural health grants across 167 projects. Where the money goes and why rural access matters. Community paramedics in rural Virginia visit patients ...

Treatment with telitacicept significantly reduced proteinuria in patients with immunoglobulin A (IgA) nephropathy compared with placebo, according to data from a phase 3 study involving more than 300 ...

IgA nephropathy mainly affects the kidneys, while IgA vasculitis can also involve your skin, joints, and digestive system. IgA vasculitis often appears suddenly with rash and pain, but IgA nephropathy ...

Between 20 and 50 percent of individuals with IgA nephropathy will experience kidney failure within two decades of diagnosis, though the timeline varies significantly from person to person. Regular ...